TEVA in the 13F filings
Teva Pharmaceutical Inds LTD · CUSIP 881624209
- Quarter end
- 30 Sep 2024
- the date the book describes
- Filed
- 5 Nov 2026
- latest of these filings; the earliest 31 Oct 2024
- Managers listing it
- 22
- at least, of 95 tracked, among listed positions
- Comparable managers
- 94
- filed both Q2 2024 and Q3 2024; 19 listed it in both
- Shares listed
- 138,791,173
- combined, among listed positions
- Reported value
- $2.3bn
- combined, at the quarter end
1 line marked †. Value as filed implies a price far from other filers'. Each counts in holders and value as filed, and is left out of the net change in shares.
Among the 94 comparable managers: 9 buyers (opened or added shares) and 12 sellers (trimmed or exited), at least, among listed positions. Their net change in shares is not known from listed positions, because at least one of them lists it in only one of the two quarters.
Managers listing TEVA in Q3 2024
22 of 22 holders
Largest increases and reductions, by shares
Increases
- Fidelity (FMR LLC)existing position · 62,740,763 shares now+20,762,226
- Millennium Management LLCnew position · 11,813,229 shares now+11,813,229
- Arrowstreet Capital LPexisting position · 14,897,625 shares now+9,095,106
- Viking Global Investors LPnew position · 7,567,533 shares now+7,567,533
- Two Sigma Advisers LPexisting position · 1,034,500 shares now+137,000
Reductions
- Holocene Advisors LPexisting position · 2,212,083 shares now-2,374,189
- D. E. Shaw & Co.existing position · 3,654,458 shares now-2,230,589
- Balyasny Asset Management LLCexisting position · 2,288,010 shares now-1,454,959
- Marshall Wace LLPexisting position · 2,744,982 shares now-1,427,611
- Glenview Capital Management LLCexisting position · 8,456,324 shares now-701,317
New positions and exits
New (2)
Exited (1)
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q2 2013 | 14 | $5.5bn | n.a. | n.a. |
| Q3 2013 | 16 | $5.9bn | n.a. | n.a. |
| Q4 2013 | 17 | $5.4bn | n.a. | n.a. |
| Q1 2014 | 24 | $7.7bn | n.a. | n.a. |
| Q2 2014 | 24 | $7.3bn | n.a. | n.a. |
| Q3 2014 | 25 | $7.4bn | n.a. | n.a. |
| Q4 2014 | 25 | $8.1bn | n.a. | n.a. |
| Q1 2015 | 25 | $8.7bn | n.a. | n.a. |
| Q2 2015 | 26 | $8.2bn | n.a. | n.a. |
| Q3 2015 | 23 | $8.4bn | n.a. | n.a. |
| Q4 2015 | 25 | $12.8bn | n.a. | n.a. |
| Q1 2016 | 27 | $10.3bn | n.a. | n.a. |
| Q2 2016 | 22 | $8.8bn | n.a. | n.a. |
| Q3 2016 | 25 | $7.9bn | n.a. | n.a. |
| Q4 2016 | 19 | $6.6bn | n.a. | n.a. |
| Q1 2017 | 22 | $5.9bn | n.a. | n.a. |
| Q2 2017 | 14 | $6.2bn | n.a. | n.a. |
| Q3 2017 | 15 | $3.0bn | n.a. | n.a. |
| Q4 2017 | 14 | $4.1bn | n.a. | n.a. |
| Q1 2018 | 13 | $4.8bn | n.a. | n.a. |
| Q2 2018 | 18 | $7.0bn | n.a. | n.a. |
| Q3 2018 | 18 | $6.3bn | n.a. | n.a. |
| Q4 2018 | 19 | $4.9bn | n.a. | n.a. |
| Q1 2019 | 14 | $4.7bn | n.a. | n.a. |
| Q2 2019 | 14 | $2.8bn | n.a. | n.a. |
| Q3 2019 | 11 | $2.0bn | n.a. | n.a. |
| Q4 2019 | 9 | $2.9bn | n.a. | n.a. |
| Q1 2020 | 14 | $2.0bn | n.a. | n.a. |
| Q2 2020 | 12 | $2.8bn | n.a. | n.a. |
| Q3 2020 | 7 | $2.1bn | n.a. | n.a. |
| Q4 2020 | 5 | $2.2bn | n.a. | n.a. |
| Q1 2021 | 8 | $2.6bn | n.a. | n.a. |
| Q2 2021 | 7 | $2.1bn | n.a. | n.a. |
| Q3 2021 | 6 | $1.7bn | n.a. | n.a. |
| Q4 2021 | 4 | $1.1bn | n.a. | n.a. |
| Q1 2022 | 9 | $1.4bn | n.a. | n.a. |
| Q2 2022 | 11 | $913m | n.a. | n.a. |
| Q3 2022 | 11 | $1.4bn | n.a. | n.a. |
| Q4 2022 | 11 | $1.7bn | n.a. | n.a. |
| Q1 2023 | 8 | $1.3bn | n.a. | n.a. |
| Q2 2023 | 10 | $184m | n.a. | n.a. |
| Q3 2023 | 13 | $384m | n.a. | n.a. |
| Q4 2023 | 10 | $373m | 8 | 3 |
| Q1 2024 | 16 | $666m | 8 | 6 |
| Q2 2024 | 22 | $1.8bn | 13 | 7 |
| Q3 2024 | 22 | $2.3bn | 9 | 12 |
| Q4 2024 | 18 | $3.0bn | 8 | 11 |
| Q1 2025 | 12 | $2.0bn | 7 | 6 |
| Q2 2025 | 11 | $1.8bn | 6 | 5 |
| Q3 2025 | 14 | $964m | 9 | 4 |
| Q4 2025 | 16 | $2.1bn | 18 | 22 |
| Q1 2026 | 14 | $2.0bn | 20 | 19 |
| Q2 2026 | 14 | $2.4bn | 18 | 16 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
TEVA and LLY →TEVA and JNJ →TEVA and VRTX →Choose a stock to compare with TEVA →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own TEVA, latest filings →Back to the 13F Explorer →